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Abstract 
 Purpose: Preclinical, or asymptomatic, Alzheimer’s disease (AD) refers to the presence 
of positive AD biomarkers in the absence of cognitive deficits. This research concept is being 
applied to define target populations for clinical drug development. In a prospective community-
recruited cohort of cognitively intact older adults, we compared two amyloid imaging markers 
within subjects: 18F-flutemetamol and 11C-Pittsburgh compound B (11C-PIB). 
 Methods: In 32 community-recruited cognitively intact older adults aged between 65 and 
80 years, we determined the concordance between binary classification based on 18F-
flutemetamol versus 11C-PIB according to semiquantitative assessment (standardized uptake 
value ratio in composite cortical volume, SUVRcomp) and, alternatively, according to visual reads. 
We also determined the correlation between 18F-flutemetamol and 11C-PIB SUVR and evaluated 
how this was affected by the reference region chosen (cerebellar grey matter versus pons) and the 
use of partial volume correction (PVC) in this population. 
 Results: Binary classification based on semiquantitative assessment was concordant 
between 18F-flutemetamol and 11C-PIB in 94% of cases. Concordance of blinded binary visual 
reads between tracers was 84%. The Spearman correlation between 18F-flutemetamol and 11C-
PIB SUVRcomp with cerebellar grey matter as reference region, was 0.84, with a slope of 0.98. 
Correlations in neocortical regions were significantly lower with pons as reference region. PVC 
improved the correlation in striatum and medial temporal cortex. 
 Conclusions: For the definition of preclinical AD based on 18F-flutemetamol, 
concordance with 11C-PIB was highest using semiquantitative assessment with cerebellar grey 
matter as reference region. 
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1  Introduction 
Biomarkers for Aβ accumulation in the brain play a central role in the National Institute on 
Ageing and Alzheimer’s Association (NIA-AA) research definition of preclinical Alzheimer’s 
disease (AD) [1]. Preclinical AD, also termed asymptomatic AD, refers to the presence of AD-
related pathophysiological processes, such as amyloid aggregation, in individuals who do not 
have cognitive deficits [1, 2]. Cognitively intact individuals who are amyloid-positive are at 
increased risk for cognitive decline [3, 4]. Recent methods for defining amyloid-positivity 
include positron emission tomography (PET) amyloid imaging and Aβ42 in cerebrospinal fluid 
assay. It is still largely unknown how the choice of a particular amyloid biomarker may affect the 
discrimination between amyloid-positive and amyloid-negative healthy subjects. This is 
important since an amyloid-positive status may define potential candidates for experimental (e.g. 
anti-amyloid) therapies in clinical drug development. 
18F-labeled tracers currently approved by the Food and Drugs Administration (FDA) and 
European Medicines Agency (EMA) for estimation of amyloid plaques in patients evaluated for 
cognitive decline are 18F-flutemetamol [5, 6], 18F-florbetaben [7], and 18F-florbetapir [8]. The 
cortical retention of 18F-flutemetamol has been compared to 11C-Pittsburgh compound B (11C-
PIB) [9] in clinical populations such as amnestic mild cognitive impairment (aMCI) patients 
together with clinically probable AD patients [10], or aMCI and clinically probable AD together 
with healthy controls [11], but not in cohorts consisting exclusively of cognitively intact older 
adults. This is crucial since the discriminative value of a tracer may also depend on the 
population under study. The concordance between two tracers may be better in a mixed sample of 
patients and controls then in a group consisting exclusively of cognitively normal controls. In 
cognitively intact older adults ligand retention values may lie closer to threshold than in patients 
with probable AD and it has been hypothesized that 11C-PIB could potentially outperform 18F-
labelled tracers under such conditions [12]. Other 18F-labelled amyloid tracers (18F-florbetaben 
[7], 18F-florbetapir [8], 18F-AZD4694 [13]) have also been compared with 11C-PIB within 
subjects, again mostly in clinical patient populations combined with cognitively intact older 
adults [14, 15]. For these tracers, no direct comparisons have been performed in cohorts 
consisting exclusively of cognitively intact older adults. Cognitively intact older adults who are 
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amyloid-positive constitute the target population for a number of current clinical drug 
development programmes. The success of targeted molecular therapies may critically depend on 
the presence of the drug target. Accurate ascertainment of amyloid-positivity prior to inclusion 
may constitute one of the factors that determines the success of trials in preclinical AD 
(importance of high specificity), as well as the cost of screening for eligible subjects (importance 
of high sensitivity). Moreover, in cognitively intact older adults where amyloid levels are slightly 
to markedly elevated, the precise analysis method is essential. This may be less of an issue in 
patients with clinically probable AD who are well within the abnormal range. None of the studies 
comparing 18F-flutemetamol and 11C-PIB have evaluated the effect of reference region, magnetic 
resonance image (MRI) versus PET-based normalization or partial volume correction on the 
concordance between those tracers in cognitively normal older adults. 
Therefore, the aim of this study was to directly compare 18F-flutemetamol to 11C-PIB 
within the same subjects in a prospective community-recruited cohort of cognitively intact older 
adults. We evaluated concordance between 18F-flutemetamol versus 11C-PIB binary 
classifications based on semiquantitative assessment and visual reads, as well as the correlations 
between the semiquantitative measures. We also estimated the impact of different image analysis 
methods on amyloid quantification. 
2  Materials and methods 
2.1  Participants 
Thirty-two cognitively intact older controls (mean age 72 years, SD 5) participated in this study 
(Table 1). They were recruited through advertisement in local newspapers and through websites 
for seniors as part of a larger longitudinal study, asking for healthy volunteers between 65 and 80 
years of age for participation in a scientific study at the University Hospital Leuven, Belgium, 
involving brain imaging. At screening, subjects underwent a detailed interview about medical 
history, a Mini Mental State Examination, a Clinical Dementia Rating, general physical and 
neurological examination, blood sampling, and a conventional neuropsychological assessment. 
Inclusion criteria were age between 65 and 80 years, MMSE ≥ 27, CDR = 0, and normal test 
scores on neuropsychological assessment. Inclusion was stratified for two genetic factors: BDNF 
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(met allele present or absent) and APOE (ε4 allele present or absent), as this cohort was part of a 
larger 18F-flutemetamol study in healthy controls of the interactions between these 
polymorphisms [16, 17]. Exclusion criteria were neurological or psychiatric history and brain 
lesions on structural MRI. The protocol (EudraCT: 2009-014475-45) was approved by the Ethics 
Committee University Hospitals Leuven. Written informed consent was obtained from all 
subjects in accordance with the Declaration of Helsinki.  
Second column: Mean (SD). Third column: Range. MMSE = Mini Mental State Examination; AVLT = 
Rey Auditory Verbal Learning Test; TL = total learning; DR = delayed recall; BNT = Boston Naming Test; 
AVF = Animal Verbal Fluency Test; LVF = Letter Verbal Fluency Test; RPM = Raven's Progressive 
Matrices; TMT = Trail Making Test part B divided by part A. 
2.2  Amyloid PET 
PET scans were acquired on a 16-slice Siemens Biograph PET/CT scanner (Siemens, Erlangen, 
Germany). Tracers were injected as a bolus in an antecubital vein (18F-flutemetamol mean 
activity 150 MBq, SD 5 MBq, range 134-162 MBq; 11C-PIB mean activity 363 MBq, SD 33 
Table 1: Demographic and neuropsychological characteristics.
Gender (male/female) 21/11
ApoE ε4 41%
Age (years) 72 (4.5) 65-80
Education (years) 12.6 (3.2) 8-20
MMSE (/30) 29.1 (1.1) 27-30
AVLT TL (/75) 44.4 (7.1) 33-69
AVLT DR (/15) 8.8 (2.3) 5-13
AVLT %DR 78.5 (12.5) 55-100
BNT (/60) 54.3 (4.1) 41-60
AVF (# words) 24.6 (5.2) 16-40
LVF (# words) 35.0 (11.9) 14-61
RPM (/60) 35.5 (10.0) 15-54
TMT B/A 2.3 (0.6) 1.3-3.8
!  6
MBq, range 255-420 MBq). The 18F-flutemetamol scan acquisition started 90 min after tracer 
injection and lasted for 30 min [6, 10, 16, 17]. The 11C-PIB scan was obtained within 30 days 
from the 18F-flutemetamol scan (mean 2 days, median 0 days, range -22 to 21 days). Three 
subjects could not come to the clinic within the 30 days period due to personal or health reasons 
and they received a 11C-PIB scan within 32, 39, and 118 days from the 18F-flutemetamol scan. 
Dynamic 11C-PIB scan acquisition extended from 0 to 70 min post tracer injection. Prior to PET 
acquisition, a low-dose computed tomography scan of the head was performed for attenuation 
correction. Random and scatter correction were applied. The 18F-flutemetamol measurement was 
rebinned into 6 frames of 5 min and the 11C-PIB measurement between 40 and 70 min post 
injection was also rebinned into 6 frames of 5 min each. Images were reconstructed using 
Ordered Subsets Expectation Maximization (4 iterations x 16 subsets). A structural T1-weighted 
MRI was acquired on a 3T Philips Achieva scanner (3D turbo field echo sequence, 32-channel 
Philips SENSitivity Encoding head coil: coronal inversion recovery prepared 3D gradient-echo 
images, inversion time 900 ms, TE/TR 4.6/9.6, flip angle 8˚, voxel size 0.98 x 0.98 x 1.2 mm3 
[17]). 
The 18F-flutemetamol and the 11C-PIB scans were preprocessed using Statistical 
Parametric Mapping 8 (SPM8, http://www.fil.ion.ucl.ac.uk/spm). The individual images of the 6 
frames were realigned and summed for both data sets separately. The individual’s 18F-
flutemetamol and 11C-PIB PET summed images were co-registered to the subject’s T1-weighted 
structural MRI. 18F-flutemetamol and 11C-PIB PET summed images were spatially normalized to 
the Montreal Neurological Institute (MNI) space using MRI. This was done in two steps. First, 
the MR image was spatially normalized to the SPM8 T1 template in MNI space using a unified 
segmentation approach. This generated the non-linear transformation parameters, as well as grey 
matter (GM), white matter (WM) and cerebrospinal fluid images. Next, these transformation 
parameters were applied to the individual’s co-registered 18F-flutemetamol and 11C-PIB PET 
summed images to spatially normalize them to MNI space. 
2.2.1  Semiquantitative analysis of amyloid PET 
To measure specific tracer retention, standardised uptake value ratio (SUVR) images were 
calculated from the spatially normalized summed 18F-flutemetamol images and from the spatially 
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normalized summed 11C-PIB images (voxel size 2 x 2 x 2 mm3) with the cerebellar GM used as 
reference region. The spatially standardised volumes of interest (VOIs) were identical for 18F-
flutemetamol and for 11C-PIB image analysis. The cerebellar GM was defined based on the 
automated anatomical labelling (AAL) atlas (areas 91-108) and masked inclusively with subject-
specific GM maps, with the threshold for masking set at > 0.3 [16, 17]. This reference region was 
used both for 18F-flutemetamol and for 11C-PIB images. As a secondary analysis, we also used 
pons as a reference region: this region was manually drawn on the SPM8 T1-template (13 axial 
slices of 2 mm) and then for each individual it was corrected to match the subject-specific 
anatomical boundaries of the pons based on the subject’s spatially normalized MR image. 
Our primary PET outcome measure was the mean SUVR in the composite cortical VOI 
(SUVRcomp) with cerebellar GM as reference region. The composite VOI consisted of 5 bilateral 
cortical areas [16, 17]. The spatially standardised VOIs were based on the AAL template. We also 
calculated mean SUVR in each of these regions separately and additionally in medial temporal 
(AAL 37-42), and occipital cortex (AAL 43-54), and striatum (AAL 71-74). The AAL VOIs were 
masked inclusively with subject-specific GM maps, with the threshold for masking set at > 0.3 
[16, 17]. Mean SUVR was also estimated in subcortical WM (SWM), which was defined based 
on subject-specific WM maps thresholded at > 0.5. 
The cut-offs for SUVRcomp for binary classification were defined based on independent 
datasets re-analyzed using the MRI-based PET analysis method described above. The cut-offs 
were defined based on the statistical distance between the AD group and the HC as described in 
Vandenberghe et al. (2010), that is: 18F-flutemetamol cut-off was estimated based on the 
Vandenberghe et al. (2010) dataset [10], and was equal to 1.38. The 11C-PIB cut-off was 
calculated based on 37 clinically probable AD subjects and 23 age-matched healthy controls 
(datasets from Nelissen et al. (2007) [18], Vandenberghe et al. 2010 [10], and Ahmad et al. 2014 
[19]) and was equal to 1.22. Note that the used 1.38 18F-flutemetamol cut-off is lower than the 
cut-off defined by Vandenberghe et al. (2010) or Thurfjell et al. (2014) for a purely PET-based 
approach, probably due to exclusion of more white matter signal by the current MRI-based 
method in the amyloid-negative cases. We also verified our binary case classification using the 
purely PET-based method with narrow VOIs and SUVR cut-offs with reference to cerebellar GM 
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as used by Thurfjell et al. (2014). For this method, the cut-off with the neuropathological 
modified Consortium to Establish a Registry for Alzheimer’s Disease score as standard-of-truth 
was 1.57 [20]. 
As a further secondary analysis, we performed a semiquantitative analysis based on 
partial volume corrected (PVC) data. PVC was based on the MRI using the modified Müller-
Gärtner method [16, 17, 21]. 
2.2.2  Visual reads 
18F-flutemetamol and 11C-PIB scans were visually evaluated by 3 independent readers blinded to 
all subject information: two certified nuclear medicine physicians (reader 1 K.V.L, reader 2 K.G.) 
and a certified psychiatrist (reader 3 M.V.), experienced in reading amyloid scans. All readers had 
successfully completed the GE Healthcare electronic reader training program for 18F-
flutemetamol images. The visual read was done on summed orthogonal PET images in native 
space, scaled to the image maximum intensity value and displayed with a modifiable rainbow 
(NIH) colour scale. Each reader received an individually randomized list of 18F-flutemetamol and 
11C-PIB images which were evaluated in separate sessions. Readers were asked to assign scans as 
positive or negative and to rate their overall confidence in classifying the image on a scale from 1 
to 5 (5 being the highest confidence). The final assignment was based on a majority verdict. 
2.3  Statistical analysis 
The primary analyses were intended to evaluate in cognitively intact older adults: 
1. The concordance between binary classification based on 18F-flutemetamol versus 11C-PIB 
according to semiquantitative SUVRcomp assessment.  
2. The concordance of binary visual reads of 18F-flutemetamol versus 11C-PIB. 
3. The correlation between 18F-flutemetamol and 11C-PIB SUVRcomp. Normality of data 
distribution was tested using the Shapiro-Wilk test. Correlations were evaluated using (a) 
Spearman rank correlation coefficients ρ if distributions deviated from normality, and (b) 
using slopes of linear regression m. The agreement between 18F-flutemetamol and 11C-PIB 
SUVRcomp was tested by a Bland-Altman analysis [22].  
The secondary analyses evaluated in cognitively intact older adults: 
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1. The agreement between readers of the visual classification. This was analysed by means of 
Fleiss’ Kappa (κ).   
2. Readers’ confidence in visual binary classification of the PET scans. This was analysed by 
three-factor repeated measures ANOVA, with reader (3 levels: reader 1 vs 2 vs 3) and tracer 
(2 levels: 18F-flutemetamol vs 11C-PIB) as within-subject factors, and concordance of binary 
visual reads (2 levels: concordant vs discordant) as between-subject factor.  
3. The correlation between 18F-flutemetamol and 11C-PIB SUVR in a set of 9 separate regions.  
4.  The correlation between 18F-flutemetamol and 11C-PIB SUVR values using the pons as 
reference region. 
5. The correlation between PVC-corrected 18F-flutemetamol and PVC-corrected 11C-PIB SUVR 
values. 
Statistical analyses were performed in Statistica 11 (http://www.statsoft.com/) and Matlab 
R2013b (http://www.mathworks.com). 
3  Results 
Regional and composite SUVR values of 18F-flutemetamol (W = 0.68-0.86, P  0.002) and 11C-
PIB (W = 0.69-0.87, P !  0.006) were not normally distributed. Therefore in the subsequent 
analyses we used Spearman ρ coefficient. 
 Binary classification based on semiquantitative cut-offs was concordant between 18F-
flutemetamol versus 11C-PIB in 94% of the cases (Figure 1a). Based on 18F-flutemetamol 
SUVRcomp 5 out of 32 subjects (16%) were assigned to the amyloid-positive category (Figure 1a, 
Figure 2). Based on 11C-PIB SUVRcomp, 7 out of 32 subjects (22%) were assigned to the amyloid-
positive category (Figure 1a, Figure 2). Two cases were discordant between 18F-flutemetamol and 
11C-PIB (cases 8 and 31, Figure 1a, Figure 2). These subjects were assigned to the amyloid-
negative category based on 18F-flutemetamol and to the amyloid-positive category based on 11C-
PIB. 
Concordance of binary visual reads between tracers was 84% (Figure 1b). Based on 18F-
flutemetamol scans 3 out of 32 subjects (9%) were assigned to the amyloid-positive category 




the amyloid-positive category (Figure 1b, Figure 2). Out of 5 discordant cases, one subject was 
read as positive for 18F-flutemetamol but negative for 11C-PIB (case 24, Figure 1b, Figure 2, 
Figure 3), and 4 were read as positive for 11C-PIB but negative for 18F-flutemetamol (cases 17, 
19, 29, 31, Figure 1b, Figure 2). Fleiss κ for inter-reader agreement was 0.86 for 18F-
flutemetamol, and 0.93 for 11C-PIB. 
Figure 1: Concordance between binary semiquantitative (a) and visual (b) classifications of 18F-
flutemetamol and 11C-PIB scans. (a) Dashed lines = SUVR cut-offs. (b) Red = positive scan; green = 
negative scan. Values in red and green cells = confidence levels of the readers. 
When we analysed readers’ confidence in visual classification of 18F-flutemetamol and 
11C-PIB scans we found a significant main effect of reader (F2,60 = 12.3, P = 0.00003): reader 1 
(r1) and 3 (r3) were more confident than reader 2 (r2) (r1 > r2 P = 0.0001, r3 > r2 P = 0.0006) 
(Figure 4a). We also found a significant main effect of concordance of visual classification: 
readers were more confident when classifying concordant cases compared with discordant cases 
(F1,30 = 5.1, P = 0.03) (Figure 4b). No other effects were found. 
18F-flutemetamol and 11C-PIB SUVR values were highly correlated in the composite 
cortical VOI, in all neocortical VOIs and in subcortical white matter (Table 2; Figure 5). The 
correlations  in  striatum  and medial temporal cortex were weaker (Table 2; Figure 5). The slopes   
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Figure 2: Representative summed PET images of the discordant cases between 18F-flutemetamol and 11C-
PIB scans based on semiquantitative and visual classification. For the sake of comparison we also 
displayed two positive cases who were concordantly classified by semiquantitative and visual approach. 
Brain sections show axial slices at -4, 10, 24, 38 MNI z coordinates. On the right side of the brain sections 
SUVRcomp values (at the top) and results of visual reads (VIS R, at the bottom, + positive scan, - negative 
scan) are shown. Images are scaled to a maximum intensity in an image. 
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Figure 3: Detailed view on case 24. Left upper corners show MNI coordinates. Right upper corners show 
brain orientation. Images are scaled to a maximum intensity in an image. 
Figure 4: Analysis of readers’ confidence in visual binary classification of 18F-flutemetamol and 11C-PIB 
scans. Main effect of reader (a). Main effect of concordantly versus discordantly classified cases (b). 
of linear regression were close to 1 in all neocortical regions and subcortical white matter (Table 
2; Figure 5). Slopes in striatum and medial temporal cortex were lower (Table 2; Figure 5). The 
Bland-Altman analysis [22] showed a good agreement between 18F-flutemetamol and 11C-PIB 
SUVRcomp, with a systematic bias towards higher 18F-flutemetamol SUVR values (Figure 6). 
When we applied the Thurfjell et al. (2014) PET-based processing method and autopsy 
derived SUVR cut-off with reference to cerebellar GM, 4 out of 32 18F-flutemetamol scans (13%) 
were classified as amyloid-positive. In three cases, the MRI-informed and the purely PET-based 
processing methods yielded discordant classification: two subjects were classified as amyloid-
negative  based  on  the  PET-based  method  and as amyloid-positive based on the MRI-informed  
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Figure 5: Regional correlations between 18F-flutemetamol and 11C-PIB SUVRs. WM = white matter.   
method (case 19 and 29, Figure 1b, Figure 2, SUVRcomp based on purely PET-based processing 
method 1.45 and 1.47 respectively), one subject showed the inverse pattern (case 31, Figure 1b, 
Figure 2, SUVRcomp based on purely PET-based processing method 1.61). The correlation 
between 18F-flutemetamol and 11C-PIB scans analysed by the purely PET-based processing 
method was high in composite cortical VOI and in all neocortical VOIs (Table 2). 
When  pons  was  used  as reference region, the correlation between 18F-flutemetamol and  
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Figure 6: Agreement between 18F-flutemetamol and 11C-PIB SUVRs based on Bland-Altman analysis. 
11C-PIB SUVRs was weaker in the composite cortical VOI and in neocortical VOIs. This 
difference  was  statistically  significant  in  the  lateral  parietal  VOI  (P  =  0.007) (Table 2). The 
correlation however was stronger in striatum, medial temporal cortex, and subcortical WM when 
pons was used as reference region than when cerebellar GM was used. This difference was 
statistically significant in subcortical WM (P = 0.004) (Table 2). With pons as reference region, 
the slopes of linear regression were close to 0.5 and were significantly less steep than with 
cerebellar GM as reference region in all VOIs (P < 0.0001) except for subcortical WM where 
slope was 0.9 (Table 2). 
PVC did not significantly alter ρ and slopes for the correlation between 18F-flutemetamol 
and 11C-PIB SUVR values in the composite cortical VOI or any of the neocortical VOIs (Table 
2). In striatum, medial temporal cortex and subcortical WM, PVC improved ρ or slope 
significantly (Table 2). 
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Cerebell GM = cerebellar grey matter; WM = white matter; PVC = partial volume correction; m = slope of 
linear regression; ρ = Spearman correlation coefficient. All correlations reached P ≤ 0.0001, except for the 
correlation in striatum with cerebellar GM as reference region P = 0.0003. Bold font shows significant 
differences at P < 0.05 for comparison of m and ρ with columns 2-3, respectively. Not corrected for 
multiple comparisons. 
4  Discussion 
To our knowledge this is the first study comparing 18F-flutemetamol to 11C-PIB in a cohort 
consisting exclusively of cognitively intact older adults, without patients with cognitive deficits. 
Our results provide evidence for a close correspondence between the two amyloid tracers even at 
this preclinical stage.  
We detected a few more amyloid-positive cases with 11C-PIB scan (7 out of 32) than with 
18F-flutemetamol scan (5 out of 32). This differs from previous comparisons that included only 
AD and MCI [10] or AD, MCI, together with HC [11], where concordance between 18F-
flutemetamol and 11C-PIB was 100%. In the Hatashita et al. study [11] the cut-offs for 
Table 2: Region-wise correlations between 18F-flutemetamol and 11C-PIB SUVRs for different analysis 
methods
MRI-informed method PET-based method
Cerebell GM Pons
Cerebell GM & 
PVC
Cerebell GM
Region  m ρ m ρ m ρ m Ρ
Composite cortical 0.98 0.84 0.49 0.69 0.96 0.90 0.72 0.86
Lateral frontal 0.91 0.87 0.49 0.76 0.91 0.89 0.72 0.85
Lateral temporal 1.03 0.83 0.47 0.70 1.03 0.87 0.73 0.75
Lateral parietal 1.00 0.90 0.50 0.63 0.97 0.92 0.74 0.92
Anterior cingulate 0.90 0.81 0.54 0.79 0.89 0.90 0.73 0.82
Posterior cingulate 0.99 0.86 0.56 0.78 0.98 0.83 0.72 0.92
Lateral occipital 1.03 0.77 0.43 0.72 0.94 0.86 0.67 0.84
Striatum 0.84 0.60 0.52 0.81 0.95 0.87 - -
Medial temporal 0.84 0.66 0.53 0.79 0.99 0.68 0.76 0.70
Subcortical WM 0.99 0.82 0.90 0.96 0.98 0.95 - -
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semiquantitative assessment were not defined independently from the test sample and this may 
also have contributed to this complete concordance. In our study the cut-offs were based on 
independent datasets.  
The values in the discordant cases in our study were around the cut-off, except for case 24 
(see below). Near-threshold values may render the binary division between amyloid-positive and 
-negative cases in cognitively normal individuals more difficult. Amyloid accumulation is a 
progressive process and the amyloid-positive cases are distributed over range of continuous 
values rather than bimodally. Hence, among cognitively normal controls a binary classification 
into positive and negative subjects is somewhat artificial. Individuals with the intermediate 
amyloid levels may either remain at this level or may be heading towards further pathological 
amyloid aggregation [23]. Subjects around the cut-off may be accumulating amyloid at a higher 
rate than those subjects who are further removed from the cut-off [23] and in this sense may be of 
special interest for potentially disease-modifying drug trials. To investigate the prevalence and 
the meaning of these cases with sufficient power a joint longitudinal approach including different 
centres would be necessary. In such an approach a standardized quantification of amyloid 
deposition, such as centiloid scale [24], would facilitate the comparison. Values close to threshold 
probably explain the higher rate of discordance in visual reads in our study compared to what has 
been found in AD and MCI [10, 11]. We however met one exception: in case 24, 18F-
flutemetamol SUVR was far removed from the cut-off and nevertheless the 18F-flutemetamol 
scan was read as positive by all 3 readers with relatively high confidence. When evaluating this 
scan in retrospect, the outcome of the read may have been determined by the fact that tracer 
retention was similarly low in white matter and in neocortex. As a consequence, the pattern of 
gyral indentation was lost and the cortical surface relatively even. This was not true for the 11C-
PIB scan. The similarity in 18F-flutemetamol retention between neocortex and white matter and 
the even appearance of the surface may have led to the positive read despite the low neocortical 
SUVR. This underscores the usefulness of semiquantitative measures when evaluating normal 
control 18F-flutemetamol scans. The overall confidence of readers in visual evaluation of scans 
was high, however, the confidence of all readers was lower when evaluating discordant cases 
compared with concordant cases. This indicated that a subset of scans in this population is 
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particularly difficult to read. 
As a further difference with previous comparative studies [10], the correlation between 
18F-flutemetamol and 11C-PIB SUVR values in subcortical white matter (Table 2) was higher than 
previously observed (in [10] r = 0.36). The definition of the white matter VOI may have been 
more accurate in the current study as it was based on the MRI. A white matter VOI that is defined 
based on PET may be affected by spill-over between grey and white matter and this may differ 
between 18F-flutemetamol and 11C-PIB, yielding lower correlations in previous studies [10]. 
We also evaluated how differences in the analysis method affected the concordance and 
the correlation with 11C-PIB. PVC did not substantially alter correlations between 18F-
flutemetamol and 11C-PIB in neocortical VOIs, but affected the correlation in striatum and medial 
temporal cortex in a positive sense. The latter area is known to be particularly susceptible to 
partial volume effects. Second, using pons as a reference region resulted in substantially lower 
correlations between 18F-flutemetamol and 11C-PIB in neocortical regions (Table 2). Only in 
striatum, medial temporal cortex, and subcortical WM did pons as a reference region yield better 
correlations (Table 2). Finally, the correlations of SUVRs were the same when 18F-flutemetamol 
and 11C-PIB scans were analysed with a purely PET-based method [20] compared to our MRI-
based method [16] (Table 2). It however is worth noting that the slopes for the correlations 
between 18F-flutemetamol and 11C-PIB were substantially lower for the purely PET-based method 
than when MRI was used to independently define the regions to be used for analysis of the two 
PET modalities. 
Practical implications 
The FDA and EMA approvals of amyloid imaging are for visual reads and are restricted to 
patients with cognitive decline. For research use in cognitively intact individuals, our findings 
suggest that semiquantitative assessment would be preferable above visual reads. In cognitively 
intact older individuals cerebellar grey matter would be the preferred reference region compared 
with pons. PVC would be advantageous for evaluation of medial temporal cortex and subcortical 
regions. Concordance between 18F-flutemetamol and 11C-PIB was better when regions were 
based on MRI rather than for PET-based regions. 
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Conclusion 
Our study of amyloid markers in asymptomatic older adults provides evidence that 
semiquantitative measures of 18F-flutemetamol with cerebellar grey matter as a reference are 
closely similar to what one would obtain if 11C-PIB was used, in particular if MRI is used to 
define the regions of interest. Concordance for visual reads tended to be less convincing in this 
population. 
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